Role of body mass index as a predictor of dupilumab efficacy in patients with severe chronic rhinosinusitis with nasal polyps
Our study confirmed the efficacy of dupilumab in each BMI subgroup. However, the efficacy seems to follow different timing with respect to patients' BMI. Our data suggest that patients with a compromised metabolic state present more severe disease at baseline and a possibly delayed response to dupilumab.
Authors
- Marco Borin (ORCID: https://orcid.org/0000-0003-1137-3761)
- Alberto Maria Saibene (ORCID: https://orcid.org/0000-0003-1457-6871)
- Giulia Gramellini
- Camilla Spanu (ORCID: https://orcid.org/0000-0002-7251-6546)
- Letizia Nitro (ORCID: https://orcid.org/0000-0002-0236-8728)
- Eugenio De Corso (ORCID: https://orcid.org/0000-0001-5761-7018)
- Alessandro Cantiani
- Giovanni Felisati (ORCID: https://orcid.org/0000-0001-6763-4305)
- Flavio Arnone (ORCID: https://orcid.org/0009-0005-3218-0442)
- Carlotta Pipolo (ORCID: https://orcid.org/0000-0001-6628-2117)
- Francesco Ferella (ORCID: https://orcid.org/0000-0001-8708-024X)
- Gabriele De Maio (ORCID: https://orcid.org/0009-0000-1985-8224)
- Alberto Giulio Dragonetti
Institutions
- University of Milan (IT)
- Agostino Gemelli University Polyclinic (IT)
- University Hospital Foundation (CA)
- Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda (IT)
- Ospedale San Paolo (IT)
- University of the Sacred Heart (JP)
Publication Details
- Journal
- Acta Otorhinolaryngologica Italica
- Published
- 2025-01-01
- DOI
- https://doi.org/10.14639/0392-100x-n2841
- Primary Topic
- Sinusitis and nasal conditions
- Type
- article
- Field-Weighted Citation Impact
- 0.00